Document:

License and Distribution Agreement, bioMerieux SA

 Exhibit 10.16 
 CONFIDENTIAL 
 GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT

 This GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT (this “Agreement”), entered into as of
May 29, 2010 (the “Effective Date”), by and between bioMérieux SA, a Société Anonyme (corporation) organized under the laws of France having its principal place of business at Chemin de l’Orme, 69280
Marcy l’Etoile, France (“BMX”). and BG Medicine, Inc., a corporation of the state of Delaware, having its principal place of business at 610 Lincoln Street North Waltham, MA 02451 (“BGM”). 

WITNESSETH: 
 WHEREAS, BMX and BGM have agreed that BMX will undertake the development of selected Products which shall be used on BMX’s VIDAS®/miniVIDAS® line of
instruments; 
 WHEREAS, BMX desires to promote and market Products in the Territory (as hereinafter defined);

 WHEREAS, BGM owns or otherwise controls or has rights to certain intellectual property rights which may cover
Products (“Patent Rights” as hereinafter defined); 
 WHEREAS, BGM desires to grant to BMX under
Patent Rights a license to make, have made, use, offer for sale, sell, have sold, import, distribute and have distributed Products in the Territory; and 
 WHEREAS, BMX desires to obtain such license. 
 NOW,
THEREFORE , in consideration of the mutual covenants and agreement contained herein, and upon the terms and subject to the conditions set forth below, BMX and BGM hereby agree as follows: 

ARTICLE 1. DEFINITIONS 
  

	1.1	“Affiliate” means, with respect to any Party (as hereinafter defined), any entity which controls, is controlled by or is under common control with,
such Party. As used herein, the term “control” means with respect to any entity, the power to direct or cause the direction of the management and policies of that entity, whether directly or indirectly and whether through ownership of more
than fifty percent (50%) of the outstanding voting stock or equity of an entity, by contract or otherwise. 

  

	1.2	“Calendar Quarter” means a period of three (3) consecutive calendar months of a calendar year, beginning on
January 1, April 1, July 1 or October 1. 

  

 1 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended. 

	1.3	“Change of Control” means: (a) the consolidation or merger of BGM with or into any Third Party wherein the shareholders of BGM immediately prior
to such transaction shall cease to be the holders of at least fifty percent (50%) of the outstanding securities of the surviving corporation in such transaction; (b) the assignment, sale, transfer, lease or other disposition of all or
substantially all of the assets of BGM relating to the business to which this Agreement relates; or (c) the acquisition by any Third Party or group of Third Parties acting in concert, of beneficial ownership (within the meaning of Rule 13d-3 of
the Securities and Exchange Commission (“SEC”) under the Securities and Exchange Act of 1934) of more than fifty percent (50%) of the outstanding shares of voting stock of BGM. 

 

	1.4	“Commercially Reasonable Efforts” shall mean those efforts in accordance with the subject Party’s efforts and resources normally used by it for a
product owned by it, or to which it has rights, which is of similar market potential at a similar stage in its product life, taking into account the competitiveness of the marketplace, the proprietary position of the product, the regulatory
structure involved, the profitability of the applicable product, and other relevant factors including technical, legal, scientific or medical factors. 

  

	1.5	“Confidential Information” means any proprietary, confidential, non-public information, data, samples, plans, marketing plans, reports, forecasts,
formulae, processes, technical or commercial information, trade secrets, patent applications, improvements, invention disclosures or know-how disclosed in writing by one Party to another Party under this Agreement, as well as information disclosed
in any other form and identified as “Confidential Information” at the time of disclosure, to the extent such disclosure is reduced to writing, marked “Confidential” and provided to the receiving Party within thirty (30) days
after oral disclosure. 

  

	1.6	“First Commercial Sale” means the date on which BMX (or its Affiliate or agent) first sells a Product to a Third Party in the Territory for monetary
consideration. 

  

	1.7	“Galectin-3” means the soluble galactoside-binding protein coded by the LGALS3 gene. 

 

	1.8	“Knowledge” means, with respect to BGM, the actual knowledge, after due inquiry, of the chief executive officer or any executive officer (as defined
for purposes of Section 14 of the Securities Exchange Act of 1934, as amended) of BGM. 

  

	1.9	“Party” means BMX or BGM and “Parties” means BMX and BGM. 

 

	1.10	“Patent Rights” means (a) the patents and patent applications listed on Exhibit 1.12 and: (b) all patents and patent applications
owned or controlled by BGM during the Term of the Agreement relating to Galectin-3 or Products; (c) the patents or patent applications acquired by BGM during the Term of this Agreement relating to Galectin-3 or Products; (d) all patents or
patent applications covering Galectin-3 or Products under which BGM becomes licensed and has the right to sublicense; (e) all patents arising from applications identified in (a), (b), (c) or (d); (f) any extension, renewal or reissue
of a patent identified in (a), (b), (c), (d) or (e); (g) any and all foreign counterparts or equivalents issued of any patents identified in (a) through (e); and (h) any reexamination or renewal of a patent identified in
(a) through (e). 

  

 2 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended. 

	1.11	“Product(s)” means individually and collectively Galectin-3 assay kits, Galectin-3 control kits and Galectin-3 calibrator, the manufacture, use or sale
of which would, but for the licenses granted herein, infringe a Valid Claim. 

  

	1.12	“Steering Committee” means a committee of individuals from the Parties which shall meet on a regular basis as the Parties require, which shall be
composed of equal numbers of individuals from each Party. The Steering Committee shall review Product development, Galectin-3 marker development, clinical studies and any other relevant issue regarding the Product that comes up during the Term.

  

	1.13	“Term” has the meaning set forth in Section 11.1. 

 

	1.14	“Territory” means every country in the world. 

  

	1.15	“Test” means an individual Galectin-3 assay test for a single determination of Galectin-3, the manufacture, use or sale of which would, but for the
licenses granted herein, infringe a Valid Claim; provided that a Test does not include tests used for purposes of Galectin-3 controls,Galectin-3 calibrators, or no-charge promotional sample kits. 

 

	1.16	“Third Party” means a person or entity other than BMX, BGM or any of each Party’s Affiliates. 

 

	1.17	“Valid Claim” means any claim of an issued and unexpired patent within Patent Rights that is applicable with respect to a Product, which claim has not
been held invalid or unenforceable by a decision of a court or governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal or which has not been admitted by the patentee to be invalid or unenforceable
through reissue, disclaimer or otherwise. In the event a patent has been held to be invalid or unenforceable, and an appeal is pending, such claims shall not be considered a Valid Claim until reinstated by a final decision, not subject to further
appeal, of a court or governmental agency of competent jurisdiction; provided, however, that once reinstated, a Valid Claim shall be considered a Valid Claim retroactively as if the patent had never been held to be invalid or unenforceable.

 ARTICLE 2. GRANT OF LICENSES 

 

	2.1	License Grant. BGM hereby grants to BMX and its Affiliates a royalty-bearing license under Patent Rights to make, have made, use, offer for sale, sell, have
sold, import, distribute and have distributed Products in the Territory. Products may be commercialized only under the names and brands of BMX and its Affiliates and only for use with platforms and technology owned or controlled by BMX or its
Affiliates. BMX shall not have the right to grant a sublicense to any Third Party. 

  

 3 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended. 

	2.2	Additional Licensees. BGM shall have the right to license Patent Rights to no more than four (4) Third Parties (“Other Licensees,” and
together with BMX, the “BGM Licensees”) for such Other Licensees to make, have made, use, offer for sale, sell, have sold, import, distribute, have distributed a Galectin-3 assay, whether on an automated system or not;
provided, that (a) beginning after December 31, 2014, BGM may license Patent Rights to additional Third Parties (who shall then be considered Other Licensees) to offer for sale, sell, have sold, import, distribute or have
distributed a Galectin-3 assay, and (b) no Other Licensee shall receive more favorable financial terms than those set forth in this Agreement. If BGM enters into an arrangement with any Other Licensee for a Galectin-3 assay that would
reasonably be believed to contain more favorable financial terms than those set forth in this Agreement, BGM shall so inform BMX within ten (10) days of entering such arrangement, and BMX shall be entitled to the benefit of the more favorable
financial terms of such other arrangement from the date of the arrangement with the Other Licensee. In the event BMX deems such Other Licensee’s financial terms to be more favorable and desires to license Patent Rights under such alternative
financial terms, BMX will notify BGM within ten (10) days of learning of these terms, after which the Parties will develop and execute the necessary amendments to incorporate the more favorable financial terms into this Agreement. Other
Licensees shall not have the right to grant sublicenses to any Third Party. For avoidance of doubt, BGM and the Other Licensees shall be free to enter into agreements for development, manufacturing or distribution of their products, and such
agreements shall not be considered licenses to Patent Rights for purposes of this Section 2.2. 

  

	2.3	Updates to Patent Rights. BGM shall be responsible for updating Exhibit 1.12 to include all developments and updates to all patents listed therein and
providing written notice to BMX. BMX shall have no payment obligations pursuant to Section 3.1 or 3.2 with respect to new Patent Rights unless and until BGM notifies BMX, in writing, that new patents have issued and are included within the
Patent Rights. 

 ARTICLE 3. FEES AND PAYMENTS 

 

	3.1	Product Fee (US). BMX shall pay to BGM a fee (the “Product Fee”) consisting of a product access fee of [***] (US $[***]) and a marketing service
fee of [***] ($[***]) for each Test sold by BMX (or its Affiliate or agent) to a Third Party in the US; provided, that if the CMS National Medicare Fee Limit Reimbursement level for Galectin-3 Tests falls below [***] dollars ($[***]) per Test, BMX
shall be entitled to a reduction in the Product Fee paid per Test by BMX to BGM to be negotiated by the Parties. If the Parties are unable to agree on the amount of the reduction of the Product Fee, the matter shall be resolved by the Alternative
Dispute Resolution process set forth in Section 12.12 and Exhibit 12.12. 

  

	3.2	 Product Fee (EU and Rest of the World). BMX shall pay to BGM a fee (the “Product Fee”) consisting of a product access fee of
[***] (EUR [***]) and a marketing service fee of [***] (EUR [***]) for each Test sold by BMX (or its Affiliate or agent) to a Third Party in the EU or elsewhere outside the US; provided, that if the average selling price

  

 4 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended. 

	 	 
for galectin-3 tests in those countries falls below [***] (EUR [***]), BMX shall be entitled to a reduction in the Product Fee paid per Test by BMX to BGM to be negotiated by the Parties. If the
Parties are unable to agree on the amount of the reduction of the Product Fee, the matter shall be resolved by the Alternative Dispute Resolution process set forth in Section 12.12 and Exhibit 12.12. 

 

	3.3	Product Fee for Inclusion in Panel: Panel In the event BMX sells any Test as part of a panel of tests for a point of care platform to detect Galectin-3 and one
or more other markers indicated for use in heart failure, then if such panel has an [***] price of at least [***] dollars ($[***]), or the equivalent thereof in local currency at the time of sale, and all tests in such Panel are accomplished in a
single step with a single cartridge or set of reagents (a “Panel”), then the Product Fee for Tests shall be [***] dollars ($[***]) per test. If the specific conditions for such panel are not met, the Product Fee set forth in
Section 3.1. or 3.2 shall apply. 

  

	3.4	Product Fee Payable Only Once. The Product Fee set forth in Section 3.1, 3.2 and 3.3 shall be payable hereunder only once with respect to a Test, regardless
of the number of patents set forth in Patent Rights that cover Products. 

  

	3.5	Reductions to Fees Due to Third Party Licenses. BMX, in its sole discretion, may determine that additional royalty-bearing licenses are required from Third
Parties in order to make, have made, use, offer for sale, sell, have sold, import, distribute, have distributed Products in the Territory. If BMX so determines that such licenses are required specifically to make, have made, use, offer for sale,
sell, have sold, import, distribute, or have distributed Galectin-3 assays for indications of the Product in the Territory, BMX shall notify BGM within [***] ([***]) [***] of making such determination. After notification BGM will attempt to
resolve the matter in a timely manner and to BMX’s satisfaction. However, if BMX, at any time, in its sole discretion, determines that such license is required [***] and [***] obtains the additional royalty-bearing licenses, BMX has the right
to deduct the royalties actually paid to such Third Parties from the fees payable to BGM; provided, that such deduction shall not be for more than [***] percent ([***]%) of the amounts otherwise due and payable to BGM hereunder.

  

	3.6	Payments. All payments shall be made quarterly. BMX shall pay BGM within thirty (30) days of the relevant invoice date. 

 

	3.7	Product Fee Reports. Within thirty (30) days of the end of each Calendar Quarter during which sales occurred, BMX shall deliver to BGM a report describing
on either a country by-country or territory-by-territory basis the number of Tests sold by BMX and its Affiliates. 

  

	3.8	Currency Conversion. All payments made hereunder shall be in US Dollars. 

  
 5 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

	3.9	Transfer of Payments. All payments due and payable hereunder to BGM shall be made by wire transfer to the following bank account number or such other bank or
other location as may be designated in writing by BGM from time to time: 

 Wire Transfer Information:

 Bank Name: [***] 
 Bank Address: [***] 
 Account Number: [***] 

Swift Code: [***] 
  

	3.10	Tax Withholding. Insofar as any fees that are due to BGM under this Agreement with respect to sales of Products outside the United States are subject to taxation
where the taxes are imposed on BGM, BGM shall bear all such taxes. BGM hereby authorizes BMX to withhold such taxes from the payments that are payable to BGM hereunder if BMX is either: (a) required to do so under the tax laws of the country of
sale or its country of incorporation; or (b) directed to do so by an agency of such government. BMX shall provide BGM with the best available evidence of payment whenever BMX deducts such taxes from any payment due BGM. Where any sum due to be
paid to BGM is subject to any withholding or similar tax, the Parties shall use Commercially Reasonable Efforts to do all such acts and things and to sign all such documents as will enable them to take advantage of any applicable double taxation or
tax reduction agreement or treaty. If there is no applicable double taxation or tax reduction agreement or treaty, or if an applicable double taxation or tax reduction agreement or treaty reduces but does not eliminate such withholding or similar
tax, BMX or its Affiliates shall pay such withholding or similar tax to the appropriate government authority, deduct the amount so paid from the amount otherwise due and payable to BGM, and secure and send to BGM the available evidence of such
payment. 

  

	3.11	Record Keeping; Audits. BMX shall keep full and accurate accounting records of all Tests sold in sufficient detail to determine the Product Fees payable by BMX
to BGM. Upon reasonable written notice to BMX, BGM shall have the right, during normal business hours, to have an independent certified public accountant, selected by BGM and acceptable to BMX, audit BMX’s records pertaining to the number of
Tests sold on a confidential basis to verify the Product Fees payable pursuant to this Agreement; provided, however, that such audit shall not: (a) take place more frequently than [***] per [***]; and (b) cover records for
more than the preceding [***] ([***]) [***]. Such certified public accountant shall enter into a non-disclosure agreement with confidentiality provisions at least as stringent as those set forth in this Agreement, and shall only disclose the
conclusion of such audit to BGM and BMX, and not any of BMX’s customers, pricing or other Confidential Information. The results of such audit shall be [***]. Any adjustment in payment shall be made upon demonstration of any underpayment or
overpayment. 

  
 6 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

	3.12	Cost of Audits. All fees and expenses of any audit requested by BGM pursuant to Subsection 3.11 shall be borne by BGM; provided, however,
that if any audit reveals that BMX underpaid Product Fees due to BGM under this Agreement as to the time period being audited by more than [***] percent ([***]%) of the amount that was payable for such time period, and as long as the underpayment
amount is at least [***] ($[***]), BMX, in addition to paying BGM any underpayment, shall reimburse BGM for the cost of such audit. 

 ARTICLE 4. GALECTIN-3 DEVELOPMENT AND PROMOTIONAL ACTIVITIES 
  

	4.1	 BMX’s Development Efforts. During the Term of this Agreement, BMX shall use Commercially Reasonably Efforts to develop, test and obtain
regulatory approval to sell Products throughout the Territory, but in any event in the United States and the European Union. Without limiting the generality of the foregoing, BMX shall initially develop a Product for use on its VIDAS®/miniVIDAS® system, and thereafter may develop Products for use on other diagnostic platforms owned or controlled by BMX and sold under trademarks of BMX (including the planned
Magnotech-based product to be developed in conjunction with Philips Healthcare). The Parties will develop a development plan and timeline for such development as set forth in Exhibit 7.1. 

 

	 	BMX agrees that it will [***] for any [***] in any jurisdiction unless and until it has [***] for a [***] in such jurisdiction and launched such Product in such
jurisdiction. 

  

	4.2	BMX’s Sales Efforts. During the Term of this Agreement, BMX shall use Commercially Reasonable Efforts to promote, market, sell and distribute Products
throughout the Territory. Such efforts may include preparing collateral marketing materials, conducting advertising, presenting educational seminars, detailing, displaying exhibits at trade shows and ensuring representation and attendance at
industry meetings, all of which shall be performed in accordance with BMX’s usual and customary practices that BMX would use for BMX’s products of a similar nature. BMX solely shall be responsible for the costs incurred in such efforts
hereunder. As part of its promotion and marketing efforts, BMX may elect to offer Products to potential customers at no charge for evaluation purposes, which Products shall not be subject to Section 3.1, 3.2 or reported pursuant to
Section 3.7. 

  

	4.3	Selling Price. BMX, in its sole discretion, shall determine the final sales price of Products sold by BMX to Third Parties in the Territory, and no other term or
provision of this Agreement shall be interpreted or deemed to provide BGM with any right to determine or influence the final sales price of Products sold by BMX hereunder. 

 

	4.4	 Development of Promotional and Marketing Materials for Products. Promptly following the Effective Date, BGM shall deliver to BMX copies of any
promotional marketing materials owned or controlled by BGM that may be used by BMX in the promotion and sale of Products. BGM represents and warrants that the statements made in any

  
 7 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	 
promotional marketing materials owned or controlled by BGM and provided to BMX shall be accurate and complete in all material respects. BMX also shall have the right to develop and prepare, at
BMX’s sole discretion and at its own cost, promotional and marketing materials for use in its sale and distribution of Products. BMX shall be responsible for the accuracy of all statements made in all materials developed by BMX.

  

	4.5	Steering Committee Meetings. The Steering Committee shall meet no less frequently than quarterly to review the progress of the development of Products by BMX,
the activities of BGM described in Section 5.1, any Product Inventions or Indication Inventions of either Party, and such other topics related to Galectin-3 or Products as either Party may request. 

 

	4.6	Exclusivity. During the Term, BMX shall not manufacture or commercialize a Galectin-3 assay other than Product if such other assay would fall within the claims
in the patents included in the Patent Rights and for so long as BGM holds all Patent Rights and intellectual property necessary to sell Products subject to these claims. 

 

	4.7	No Excluded Parties. During the Term, BMX shall not deny the sale or supply of Product to any laboratory service provider meeting standard or customary BMX
customer criteria and willing to purchase Product on standard terms. 

 ARTICLE 5. CLINICAL STUDIES AND
CLINICAL INDICATIONS 
  

	5.1	Clinical Studies and Clinical Indications. BGM shall use Commercially Reasonable Efforts to validate the clinical use of Galectin-3 as described on Exhibit
5.1 and any amendments added to Exhibit 5.1 by mutual written agreement of the Parties. The Parties shall discuss the protocols, intended use objectives, status, results and opportunities for expanded clinical claims for the Products
during the quarterly Steering Committee meetings. 

  

	5.2	FDA Approval. If BGM has not obtained FDA approval for a clinical claim for Galectin-3 in the prognosis of patients with heart failure prior to BMX initiating
clinical trials for the same claim, BMX will be entitled to terminate this Agreement by written notice to BGM, without incurring any liability whatsoever. In such a case of termination, Section 11.3 shall not apply. 

ARTICLE 6. INTELLECTUAL PROPERTY 
  

	6.1	Inventions Covering Product. BGM shall own all right, title and interest in and to all inventions during the Term specifically covering the rare reagents used in
the Product (“Product Inventions”) and inventions covering indications for the use of Galectin-3 (“Indication Inventions”), conceived and reduced to practice solely by BGM. If Product Inventions or Indication
Inventions are conceived and reduced to practice hereunder jointly by BMX and BGM (“Joint Inventions”) US inventorship laws shall govern the ownership of such Joint Inventions. All Product Inventions and Indication Inventions
hereunder owned or controlled by BGM during the Term shall become part of Patent Rights hereunder. 

  

 8 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended. 

	6.2	BMX’s Galectin-3 Intellectual Property. If BMX solely conceives and reduces to practice any new Product Inventions or Indication Inventions that result in
new patents being sought to cover such new reagents or indications, BMX shall own such Product Inventions and Indication Inventions, and shall make such Product Inventions and Indication Inventions available to BGM and the Other Licensees on a
non-exclusive, royalty-free basis during the Term strictly for use related to Product(s). BMX, in its sole discretion and for its own benefit, shall have the right to exploit such BMX-owned Product Inventions and Indication Inventions in the
Territory. 

  

	6.3	BGM Licensee Galectin-3 Intellectual Property. BGM shall use Commercially Reasonable Efforts to contractually require of each Other Licensee that if an Other
Licensee conceives, reduces to practice, owns controls (through sublicensing or otherwise) any new Product Inventions or Indication Inventions pertaining to Products that are patented or that result in new patents being sought, then BMX shall be
granted a non-exclusive, royalty-free license, during the Term, to make, have made, use, offer for sale, sell, have sold, import, distribute and have distributed Products using such new Product Inventions or Indication Inventions.

  

	6.4	Patent Prosecution. Each Party shall be solely responsible for the filing and prosecution of patent applications claiming inventions owned by such Party. Unless
otherwise agreed by the Parties, the Parties will jointly file and prosecute patent applications for Joint Inventions. 

 ARTICLE 7. INFRINGEMENT AND ENFORCEMENT 
  

	7.1	Patent Enforcement. 

  

	 	7.1.1	Notice and Investigation of Infringement. Each Party shall promptly notify the other Party of any possible infringement of BGM’s patents included in Patent
Rights by a Third Party of which such Party has knowledge. BGM shall promptly investigate such possible Third Party infringement and shall inform BMX of its findings with respect thereto within thirty (30) days of such notice, or such longer
period as is required to determine if infringement is occurring. 

  

	 	7.1.2	 BGM Actions and Participation. During the Term, BGM shall have the right, but not the obligation, to enforce any and all claims of infringement
of any BGM patents included in Patent Rights and any patents claiming a Joint Invention or any related proprietary rights, in its own name, at its own expense and for its own benefit, and BMX shall take reasonable actions to enable BGM to enforce
such action in BGM’s own name, including, but not limited to, the execution of any necessary papers. BMX shall join BGM as a party to such prosecution if it is reasonably determined by BGM that BMX is a necessary party to such

  

 9 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended. 

	 	 
prosecution, whereupon BGM shall bear all costs and control such litigation as if such action had been brought solely in BGM’s name. BGM shall have the right to control all aspects of the
enforcement of any claim against a Third Party brought pursuant to the provisions of this Subsection 7.1.2, including, but not limited to, the right to: (a) select counsel; (b) establish litigation strategies; and (c) pursue
settlement discussions and enter into settlements. BMX shall have the right, at its option and costs, to join any such action by BGM in order to seek damages the relevant infringement has caused BMX. 

 

	 	7.1.3	BMX Action. BMX understands that BGM has previously granted to Abbott Laboratories the right, but not the obligation, to enforce any and all claims of
infringement of any Patent Right if BGM does not do so. In the event both BGM and Abbott Laboratories do not pursue enforcement of any Patent Right or in case BGM does not pursue enforcement of any patents claiming a Joint Invention as set forth in
Subsection 7.1.2, and BMX reasonably believes that such infringement shall materially impact BMX’s ability to market the Products, BMX shall have the right, but not the obligation, to enforce any and all claims of infringement of any
patents claiming a Joint Invention or any Patent Right against such infringement, in its own name, at its own expense and for its own benefit, and BGM agrees to take all actions reasonably necessary to enable BMX to enforce such action in its own
name, including, but not limited to, the execution of any necessary papers. BGM shall join BMX as a party to such prosecution if it is reasonably determined that BGM is a necessary party to such prosecution, whereupon BMX shall bear all costs and
control such litigation as if such action had been brought solely in BMX’s name. BMX shall have the right to control all aspects of the litigation of any claim against a Third Party brought pursuant to the provisions of this Subsection
7.1.3, including, but not limited to, the right to: (a) select counsel, such selection to be subject to BGM’s written approval, such approval not to be unreasonably withheld; (b) establish litigation strategies, subject to an
obligation to confer with BGM regarding such strategies and to give reasonable consideration to BGM’s input with respect to such strategies; and (c) pursue settlement discussions and enter into settlements. Notwithstanding the foregoing,
BMX shall not settle any such litigation or claim without the prior written consent of BGM, which consent shall not be withheld unreasonably. For clarity, nothing in this Section 7.1.3 shall require BGM to take or permit any action that would
violate BGM’s agreement with Abbott Laboratories. 

  

	 	7.1.4	Proceeds Recovered. Any amount received by BMX as a result of any proceeding referred to in Subsection 7.1.3, shall be distributed and paid as follows:
(a) first, to reimburse BMX for all expenses incurred by it in connection with such proceeding; (b) second, to reimburse BGM for any expenses incurred by it in connection with such proceeding; and (c) third, any additional amounts
remaining after such application shall be [***]. 

  
 10 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	7.1.5	Cooperation. The Party controlling the action shall keep the other Party reasonably informed of the progress of the suit, claim or proceeding.

  

	7.2	Defense of Assertions of Infringement of Third Party Patents 

  

	 	7.2.1	Assertion Against BMX. In the event of a Third Party assertion against BMX of patent infringement (or any other violation of a proprietary right of a Third
Party) related to the manufacture, use or sale of the Product(s) in the Territory, BMX shall defend such assertion, at its sole discretion and at its sole expense. BMX shall promptly notify BGM in writing of the assertion or claim, including details
and known facts regarding such assertion or claim. BGM shall provide, upon BMX’s request and at BMX’s sole expense, reasonable assistance for such defense. BMX shall have the right to settle such assertion on terms acceptable to BMX;
provided, however, that BMX shall not enter into any settlement that would affect BGM’s Patent Rights relating to Products without the prior, written consent of BGM. 

ARTICLE 8. REPRESENTATIONS AND WARRANTIES 
  

	8.1	General Representations and Warranties. Each Party represents and warrants to the other Party as of the Execution Date of this Agreement:

  

	 	(a)	It is a corporation duly organized and validly existing under the laws of its state of incorporation; 

 

	 	(b)	It has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder; 

 

	 	(c)	At no time prior to the termination or expiration of this Agreement, shall BGM enter into any transaction which would prohibit or materially impair BGM from fulfilling
its obligations under this Agreement. 

  

	8.2	Patent Representations and Warranties. BGM represents and warrants to BMX the following as of the Execution Date of this Agreement: 

 

	 	(a)	It is the sole owner of all right, title and interest in and to the patents included in Patent Rights, and no approvals or other documentation are necessary to be
obtained from any Third Party in order for the licenses and rights to be conferred to BMX hereunder; 

  

	 	(b)	There have been no written claims or assertions, or to BGM’s Knowledge any oral claims or assertions, that the making, using, offering for sale, use, or importing
of one or more of the Products infringes the patents or other proprietary right of any Third Party; 

  

 11 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended. 

  

	 	(c)	BGM has no Knowledge of any Third Party patents, trademarks or other proprietary rights which are valid and which would be infringed by making, having made, using,
selling, offering for sale or importing Products in the Territory in accordance with the terms of this Agreement; and 

  

	 	(d)	To its Knowledge, BGM is not, and as a result of the execution and delivery of this Agreement, will not be, in violation of, or lose of any rights pursuant to, any
license, sublicense or agreement previously provided to BGM by a Third Party with respect to Patent Rights relating to Products. 

  

	8.3	Not Inferior Business Terms. BGM represents and warrants to BMX the following as of the Execution Date of this Agreement: 

 

	 	Subject to the effect of currency fluctuations, it has not granted any product license for the development and manufacturing of a galectin-3 assay for automated
laboratory instruments on substantially superior terms to the terms granted to BMX and that the aggregate of product fees, marketing fees and other licensing fees are comparable to the fees under this agreement ([***]). 

 

	8.4	BMX Representations and Warranties. BMX represents and warrants to BGM the following as of the Execution Date of this Agreement: 

 

	 	(a)	BMX [***] of any [***] in order to make, have made, use, offer for sale, sell, have sold, import, distribute, have distributed Products in the Territory; and
(b) BMX [***] or [***] related to [***], or [***] to [***] from a [***] to [***]. 

  

	8.5	Debarment and Exclusion. BGM represents and warrants that neither it, nor any of its employees or agents working on the subject matter of this Agreement, has
ever been, is currently, or is the subject of a proceeding that could lead to it becoming, as applicable, a Debarred Entity or Individual, an Excluded Entity or Individual or a Convicted Entity or Individual. BGM further covenants, represents and
warrants that if, during the Term of this Agreement, it, or any of its employees or agents working on BMX’s behalf, becomes or is the subject of a proceeding that could lead to that Party becoming, as applicable, a Debarred Entity or
Individual, an Excluded Entity or Individual or a Convicted Entity or Individual, BGM shall immediately notify BMX, and BMX shall have the right to immediately terminate this Agreement. This provision shall survive termination or expiration of this
Agreement. For purposes of this provision, the following definitions shall apply: 

  

	 	(a)	A “Debarred Individual” is an individual who has been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or (b) from providing services
in any capacity to a person that has an approved or pending drug product application. 

  

	 	(b)	A “Debarred Entity” is a corporation, partnership or association that has been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or
(b) from submitting or assisting in the submission of any abbreviated drug application, or a subsidiary or Affiliate of a Debarred Entity. 

  
 12 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	(c)	An “Excluded Individual” or “Excluded Entity” is (i) an individual or entity, as applicable, who has been excluded, debarred,
suspended or is otherwise ineligible to participate in federal health care programs such as Medicare or Medicaid by the Office of the Inspector General (OIG/HHS) of the U.S. Department of Health and Human Services, or (ii) is an individual or
entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in federal procurement and non-procurement programs, including those produced by the U.S. General Services Administration (GSA).

  

	 	(d)	A “Convicted Individual” or “Convicted Entity” is an individual or entity, as applicable, who has been convicted of a criminal offense
that falls within the ambit of 42 U.S.C. § 1320a – 7(a), but has not yet been excluded, debarred, suspended or otherwise declared ineligible. 

  

	8.6	Limitation on Warranties. NEITHER PARTY MAKES ANY OTHER WARRANTIES OTHER THAN THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, AND EXCEPT AS STATED IN THIS
AGREEMENT, THERE SHALL BE NO IMPLIED OR STATUTORY WARRANTIES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. 

 

	8.7	Additional Representation and Warranty. Each Party represents and warrants to the other Party as of the Execution Date, that the execution, delivery and
performance by it of this Agreement and its compliance with the terms and provisions thereof does not and will not conflict with or result in a breach of any other material agreement or relationship, which breach will materially and adversely affect
such Party’s ability to perform its obligations hereunder. 

 ARTICLE 9. INDEMNIFICATION

  

	9.1	BGM Indemnification. BGM shall indemnify, defend and hold BMX and its Affiliates and their officers, directors, employees and representatives collectively,
(“BMX Indemnitees”) harmless from and against any and all losses, damages, demands, fees, expenses, fines, penalties and costs (including reasonable attorney’s fees) (hereinafter, “Losses”) to the extent that
such Losses arise out of, relate to or are in connection with claims, causes of action, suits or proceedings of Third Parties (hereinafter “Claims”) resulting from: (a) the material breach of BGM’s warranties,
representations or covenants set forth in this Agreement; (b) gross negligence or willful misconduct on the part of BGM, including its employees, agents or representatives. 

  

 13 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended. 

  

	9.2	BMX Indemnification. BMX shall indemnify, defend and hold BGM and its Affiliates and their officers, directors, employees, and representatives (collectively,
“BGM Indemnitees”) harmless from and against any and all Losses, to the extent that such Losses arise out, relate to or are in connection with Claims resulting from: (a) the material breach of BMX’s warranties,
representations or covenants set forth in this Agreement; (b) gross negligence or willful misconduct on the part of BMX, including its employees, agents or representatives, or (c) the use, sale or import by BMX or any of its Affiliates,
distributors or agents, of any Product or the use of any Product by or in the diagnosis or treatment of any Third Party. 

  

	9.3	Offsetting Claims. With respect to any Claim for which BGM has an obligation to any BMX Indemnitee pursuant to Section 9.1 and BMX has an obligation to any
BGM Indemnitee pursuant to Section 9.2, each Party shall indemnify each of the other Party’s Indemnitees for its Losses to the extent of its responsibility, relative to the other Party, for the facts underlying the Claim.

  

	9.4	Cooperation. With respect to any Claim for which a Party seeks indemnification (“Indemnitee”) from any other Party
(“Indemnitor”) under this Article 9, the Indemnitee shall: (a) promptly advise the Indemnitor in writing of any Claim within [***] ([***]) [***] after the Indemnitee received notice of such Claim, or within such period of
time so as not to materially prejudice the right of the Indemnitor with regard to the defense of such Claim (whichever time period is shorter); and (b) assist the Indemnitor and its representatives in the investigation and defense of any Claim
for which indemnification is provided. The Indemnitor shall defend, and control the defense of, any such Claim, and shall not offer to settle, settle or otherwise compromise such Claim without the Indemnitee’s prior written consent (which
consent will not be unreasonably withheld), unless such settlement fully releases the Indemnitee without any liability, loss, cost or obligation. 

  

	9.5	IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY INDIRECT, SPECIAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES, LOSSES, COSTS OR EXPENSES OF ANY KIND, HOWEVER CAUSED ON ANY
THEORY OF LIABILITY AND WHETHER BASED IN CONTRACT OR TORT (INCLUDING NEGLIGENCE), INCLUDING LOST PROFITS OR REVENUES AND LOSS OF GOODWILL, REGARDLESS OF WHETHER SUCH PARTY KNOWS OR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSSES. THE
PARTIES HEREBY WAIVE THE RIGHT TO PUNITIVE DAMAGES. 

 ARTICLE 10. CONFIDENTIALITY AND PUBLIC
ANNOUNCEMENTS 
  

	10.1	 Confidentiality. The Parties acknowledge and agree that during the Term, each of them and their Affiliates may exchange Confidential
Information, and the disclosure and use of any such Confidential Information shall be governed by the provisions of this Section 10.1. Each Party (“Receiving Party”) shall use the Confidential Information of the other Party
(“Disclosing Party”) only for the purpose of the activities contemplated by this Agreement and shall not disclose such Confidential Information to a Third Party except in accordance with the provisions of this Agreement. The Parties
shall ensure that their 

  
 14 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	 
Affiliates keep all Confidential Information exchanged hereunder confidential in accordance with the provisions hereof as though the Affiliates were parties hereto. This provision shall remain in
effect for a period of [***] ([***]) years after termination or expiration of this Agreement for all Confidential Information excluding Trade Secrets (as defined in Section 10.2). Trade Secrets shall be kept confidential by the Receiving
Party (as defined in Section 10.2 hereof) according to the terms set forth in Section 10.2. The provisions of this Section 10.1 shall not apply to any information which: 

 

	 	(a)	Is known to the Receiving Party before receipt thereof under this Agreement, as evidenced by the Receiving Party’s written records; 

 

	 	(b)	Is disclosed to the Receiving Party without restriction by a Third Party (as hereinafter defined) that is, to the Receiving Party’s knowledge, not under an
obligation of nondisclosure to the Disclosing Party; 

  

	 	(c)	Is or becomes part of the public domain other than through a breach of this Agreement by the Receiving Party; 

 

	 	(d)	Is independently developed by or for the Receiving Party without use of the Disclosing Party’s Confidential Information, as evidenced by the Receiving Party’s
written records; 

  

	 	(e)	In any case in which it is disclosed by the Receiving Party with the Disclosing Party’s prior written approval; or 

 

	 	(f)	In any case in which it is required by law to be disclosed; provided, that in such instance the Receiving Party will provide the Disclosing Party with at least
ten (10) business days notice prior to making the required disclosure (or as much notice as possible if the disclosure is required to be made in less than ten (10) business days) in order to allow the Disclosing Party to review such
disclosure and to take appropriate measures to protect the confidentiality of its Confidential Information; provided further, that to the extent the Disclosing Party is unsuccessful in protecting against disclosure of its Confidential
Information, the Receiving Party shall only disclose such Confidential Information to the minimum extent required to comply with applicable law. 

  

	10.2	 Handling of Trade Secrets. During the course of its performance hereunder, a Party (the “Disclosing Party”) may desire or be
requested to disclose Confidential Information to the other Party (the “Receiving Party”), which the Disclosing Party considers a trade secret (“Trade Secret”). In such event, the Disclosing Party first shall inform
the Receiving Party, on a non-confidential basis, of the general nature of the Trade Secret information. The Receiving Party shall have [***] ([***]) [***] to decide whether it wishes to have such Trade Secrets disclosed to it and to inform the
Disclosing Party in writing that it wishes to receive such a disclosure. Any Trade Secrets so disclosed between the Parties shall be marked “Trade Secret,” and the Receiving Party shall not disclose or use

  
 15 

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application
requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	 
such Trade Secret for the Term and thereafter except as expressly permitted under this Agreement. In the event the Disclosing Party discloses the Trade Secrets to the Receiving Party without
written approval of the Receiving Party and/or without appropriately marking such information as “Trade Secret” that trade secret shall be handled as Confidential Information under Section 10.1. 

 

	10.3	Confidential Treatment. Each Party shall seek confidential treatment for the terms and conditions of this Agreement to the fullest extent permitted by the SEC
and any other governmental agency or self-regulatory organization to which a Party provides a copy of this Agreement. Prior to seeking confidential treatment from the SEC or any other governmental agency or self-regulatory organization for any such
document, the filing Party shall provide the other Party and the other Party’s counsel with a copy of the proposed filing showing the filing Party’s proposed redactions of the document, and shall consult with the other Party and the other
Party’s counsel and provide them with a reasonable opportunity to request the inclusion of specified provisions or redactions in any request for confidential treatment. 

 

	10.4	Permitted Disclosure. Notwithstanding Section 10.1, disclosure of the Disclosing Party’s Confidential Information and of this Agreement and the terms
hereof may be made by the Receiving Party: (I) (a) on a need-to-know basis to the Receiving Party’s legal and financial advisors; (b) as reasonably necessary in connection with an actual or potential (i) debt or equity
financing of the Receiving Party or (ii) Change of Control involving the Receiving Party; and (c) to any Third Party to enable the Receiving Party to exercise its rights and perform its obligations under this Agreement; if, in the case of
clauses (a) (except with respect to disclosures to the Receiving Party’s legal advisors), (b) and (c), the person or entity receiving such Confidential Information of the Disclosing Party is bound by written or professional
obligations substantially as restrictive as those contained in Section 10.1, and (II) as reasonably necessary for the Receiving Party to file, prosecute and maintain Patent Rights, or to file, prosecute or defend litigation against Third
Parties related to Patent Rights, in accordance with this Agreement; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available.

  

	10.5	Press Announcements. The terms of this Agreement shall be considered Confidential Information. As soon as reasonably practicable after the Effective Date, the
Parties shall issue a joint public announcement of the execution of this Agreement in a form agreed upon by the Parties and approved through their respective corporate approval processes. Neither Party shall make any public announcement concerning
this Agreement, nor make any public statement which includes the name of any other Party or any of its Affiliates, or otherwise use the name of any of the other Parties or any of their Affiliates in any public statement or document, except as may be
required by law or judicial order, without the written consent of each of the other Parties, which written consent shall not be withheld unreasonably. Once a Party has consented to public disclosure of its Confidential Information pursuant to this
Section 10.5, the other Party may make subsequent public disclosures of the same Confidential Information without further consent. 

  

 16 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 ARTICLE 11. TERM AND TERMINATION 

 

	11.1	Term; Termination for Breach. This Agreement shall commence on the Effective Date, and unless terminated early pursuant to the provisions of this Agreement,
shall expire on the expiration date of the last-to-expire patent in Patent Rights that covers Product (“Term”). Either Party may terminate this Agreement upon sixty (60) days written notice to the other Party if the other Party
materially breaches this Agreement and such breach is not cured within such sixty (60) day period. 

  

	11.2	BMX Termination. BMX shall have the right to terminate this Agreement on thirty (30) days written notice to BGM without further payments due to BGM, other
than payment obligations that have accrued prior to termination, if BMX determines that any of the following occurs: 

  

	 	(a)	BGM is under government or other regulatory restrictions /compliance restrictions relating to Product, or 

 

	 	(b)	BMX is aware of possible infringement by Product of Third Party patents or has been contacted by a Third Party regarding patent infringement relating to Product, or

  

	 	(c)	The predicate device (microplate) does not get regulatory clearance in the US by December 31, 2010, or 

 

	 	(d)	A new marker shows superior clinical utility and is adopted by the physician community. 

 

	11.3	Consequences of Termination. If BMX, in its sole discretion, voluntarily, and for reasons within its control (i.e., for reasons other than those set forth in
Section 11.2), discontinues the Product’s development program, or discontinues the sale of Products as contemplated by this Agreement, then BMX may terminate this Agreement upon thirty (30) days written notice to BGM, in which event
BMX shall allow BGM to sell Products designed for use on BMX diagnostic systems pursuant to the terms and conditions of a distribution arrangement negotiated in good faith between the Parties, including fair compensation for BMX’s R&D
investments. 

  

	11.4	Accrued Rights and Obligations. The termination or expiration of this Agreement shall not relieve any Party of any obligation arising under this Agreement which
shall have accrued prior to such expiration or termination. 

  

	11.5	Survival. The following Articles and Sections shall survive the expiration or termination of this Agreement: Articles 1, 8, 9, 10 and 11 and Sections 3.9, 3.10,
3.11, 3.12, 6.1, 6.2, 6.4, 7.1.4 and 7.1.5. All provisions that survive termination, that are irrevocable or that arise due to termination shall survive in accordance with their terms. Any provisions of this Agreement contemplated by their terms to
pertain to a period of time following termination or expiration of this Agreement shall survive only for the specified period of time. 

  

 17 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 ARTICLE 12. MISCELLANEOUS 

 

	12.1	Force Majeure. No Party shall be liable for loss, damage, detention or delay resulting from any cause whatsoever beyond its reasonable control or resulting from
a force majeure, including, without limitation, fire, flood, strike, lockout, civil or military authority, insurrection, war, embargo, container or transportation shortage or delay of suppliers, and delivery dates shall be extended to the extent of
any delays resulting from the foregoing or similar causes. The Party so affected shall give prompt notice to the other Party of such cause, and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as
reasonably possible. The party giving such notice shall be excused from such of its obligations hereunder for so long as it is so disabled or for thirty (30) days after notification to the other Party, whichever is longer; provided,
however, that such affected Party commences and continues to take reasonable and diligent actions to cure such cause. Notwithstanding the foregoing, nothing in this Section 12.1 shall excuse the obligation to make any payment due
hereunder in the manner and time provided. 

  

	12.2	Assignment. No Party hereto shall have the right to assign any of its rights or obligations under this Agreement to a Third Party without the prior written
consent of each of the other Party, which consent shall not be withheld unreasonably; provided, however, that without such consent, a Party may assign this Agreement in whole or in part to an Affiliate of the assigning Party or in
whole, but not in part, to any purchaser of all or substantially all of its assets to which this Agreement relates or to any successor corporation resulting from any Change of Control. 

 

	12.3	Binding Effect. This Agreement shall be binding upon and inure to the benefit of each Party hereto and its successors and assigns. 

 

	12.4	Relationship of the Parties. The relationship of the Parties hereunder is that of independent contractors. Nothing contained in this Agreement shall be construed
so as to constitute the Parties as partners, joint ventures or agents of the other. No Party or its Affiliates has any express or implied right or authority under this Agreement to assume or create any obligations or make any representations or
warranties on behalf of or in the name of the other Party or any of such other Party’s Affiliates. 

  

	12.5	Amendments. Except as otherwise expressly provided herein, neither this Agreement nor any provision hereof may be amended except by a written instrument signed
by each Party. 

  

 18 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended. 

	12.6	Waivers. Any waiver by any Party hereto of any rights arising from a breach of any covenants or conditions of this Agreement shall not be construed as a
continuing waiver of other breaches of the same nature or other covenants or conditions of this Agreement. 

  

	12.7	Notices. All written notices and other communications between the Parties which shall or may be given pursuant to this Agreement shall be deemed to have been
sufficiently given when delivered by personal service or sent by registered or certified mail return receipt requested, overnight delivery service providing evidence of delivery, or confirmed facsimile, to the recipient addressed as follows:

 If to BMX: 
 bioMérieux SA 
 Chemin de l’Orme, 

69280 Marcy l’Etoile, France 
 Tel: [***] 
 Fax: [***] 

Attn: [***] 

If to BGM: 
 BG Medicine, Inc. 
 610 Lincoln Street North 

Waltham, MA 02451 

Tel: 781-890-1199 

Fax: 781-895-1119 

Attn: President & CEO 
 All such communications shall be deemed to be effective on the day on which personally served, or, if sent by registered mail, on the seventh day following the date presented to the postal authorities for
delivery to the other Party (the cancellation date stamped on the delivery or the envelope being evidence of the date of such delivery), or if by overnight delivery or facsimile, on the delivery or the facsimile date. Either Party may give to the
other Party written notice of change of address, in which event any communication shall thereafter be given to such other Party as above provided at such changed address. 

 

	12.8	Applicable Legal Requirements. Each Party shall comply with all applicable legal requirements and shall not be required to perform or omit to perform any act
required or permitted under this Agreement if such performance or omission would violate the provisions of any such applicable legal requirement. 

  

	12.9	Further Assurances. Subject to the terms and conditions of this Agreement, each Party shall cooperate with the other Party to take, or cause to be taken, all
actions and to do, or cause to be done, all things necessary or desirable under applicable laws and regulations to consummate the transactions contemplated by this Agreement. 

  

 19 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended. 

	12.10	Entire Agreement; Conflict in Terms. This Agreement is the sole understanding and agreement between the Parties hereto with respect to the subject matter hereof
and supersedes all other prior agreements and understandings with respect to the subject matter hereof. 

  

	12.11	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, excluding its conflict of laws provisions.

  

	12.12	Alternative Dispute Resolution. Any dispute or claim arising out of or in connection with this Agreement (unless otherwise set forth herein) shall be finally
settled by Alternative Dispute Resolution (“ADR”) in accordance with the process set forth on Exhibit 12.12. 

  

	12.13	Interpretation. Where the context hereto requires, the singular number shall be deemed to include the plural and vice-versa. The headings of the Articles,
Sections and Subsections of this Agreement have been added for the convenience of the Parties and shall not be deemed a part hereof or used in the interpretation of this Agreement. In any context herein, “or” is not exclusive;
“including” and “include” are not exclusive and are deemed to be followed by the words “without limitation.” 

  

	12.14	Severability. If any provision of this Agreement is finally held to be invalid, illegal or unenforceable by a court or agency of competent jurisdiction, that
provision shall be severed or shall be modified by the Parties so as to be legally enforceable (and to the extent modified, it shall be modified so as to reflect, to the extent possible, the intent of the Parties) and the validity, legality and
enforceability of the remaining provisions shall not be affected or impaired in any way. 

  

	12.15	Counterparts. This Agreement may be executed in two (2) original counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. 

  

	12.16	Mutual Drafting. This Agreement is the joint product of the Parties and each provision hereof has been subject to the mutual consultation, negotiation and
agreement of the Parties and each Party’s respective legal counsel and advisors, and any rule of construction that a document shall be interpreted or construed against the drafting Party shall not be applicable with respect to this Agreement.

  

	12.17	Change of Control. In the event of a Change of Control, BGM shall assign all of its obligations under this Agreement to the surviving entity in any merger or
consolidation or to any entity to which it transfer all or substantially all of its business to which this Agreement relates. By such assignment, the acquirer shall be bound by all the terms and provisions of this Agreement, and the acquirer shall
assume all the obligations of BGM under this Agreement. 

 (Remainder of Page Intentionally Left Blank)

  

 20 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be executed by its duly
authorized representative. 
  

									
	BIOMERIEUX SA	 		 	BG MEDICINE, INC.
					
	By:	 	/s/ Eric Bouvier	 		 	By:	 	/s/ Pieter Muntendam
		 	Eric Bouvier	 		 		 	Pieter Muntendam
					
		 	Title: Deputy General Manager	 		 		 	Title: President & CEO

  

 21 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule
406 of the Securities Act of 1933, as amended. 

 Exhibit 1.12 
 Patent Rights 
 BG MEDICINE INC. PATENTS and PATENT APPLICATIONS
RELATING TO GALECTIN-3 – 
 Status on April 16, 2010 

 

											
	 PATENT TITLE
	  	 DOCKET No.
	  	 COUNTRY
	  	 SERIAL or
PATENT No.
	  	 FILING DATE
	  	 STATUS

						
	 [***]
	  	[***]	  	         Europe
         PCT

        US

        Canada
         Australia

        Australia
         Japan

        China
         India

        Europe
         Hong Kong
	  	[***]	  	[***]	  	         Expired
         Expired

        Pending
         Pending

        Allowed 08Jul2009
         Pending

        Pending
         Pending

        Pending
         Pending

        Pending

						
	 [***]
	  	[***]	  	         US Provisional
         US

        PCT
	  	[***]	  	[***]	  	         Expired
         Pending

        Pending

						
	 [***]
	  	[***]	  	         US Provisional
         PCT

        US

        Australia
         Canada

        Europe
         Japan
	  	[***]	  	[***]	  	         Expired
         Expired

        Pending
         Pending

        Pending
         Pending

        Pending

						
	 [***]
	  	[***]	  	        US Provisional	  	[***]	  	[***]	  	        Pending
						
	 [***]
	  	[***]	  	        US Provisional	  	[***]	  	[***]	  	        Pending

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit 5.1 
 Clinical Studies and Clinical Indications 
 BGM use Commercially Reasonable Efforts
to perform the following activities in support of Galectin-3 clinical development. These activities shall be reviewed at the quarterly Steering Committee meetings and adjusted by mutual written agreement of the Parties. 

1) Conduct clinical studies and partnerships to confirm, extend and justify the use of Galectin-3 in the following areas. In addition,
whenever possible provide sufficient quantities of specimens from these studies to BMX to allow for submission for additional clinical indications 
  

	 	a.	Heart Failure stratification: 

	 	 	Studies reasonably anticipated to show that Galectin-3 aids in the risk stratification of Heart Failure patients and provides additional clinical information versus
other commonly used cardiac markers such as BNP, and NT-BNP. 

  

	 	b.	Device Treatment Selection: 

	 	 	Studies reasonably anticipated to show the role of Galectin-3 in identifying responders for CRT or other device treatments in classes of patients that are not currently
considered for these treatments. 

  

	 	c.	Companion Diagnostic Studies: 

	 	 	Studies reasonably anticipated to show that current drugs, not commonly used, can be better selected and efficacious for patients using Galectin-3 levels. Studies
reasonably anticipated to show that Galectin-3 may be useful in identifying heart failure patients for new drugs. 

  

	 	d.	Health Outcomes and Economic Studies: 

	 	 	Studies reasonably anticipated to show the outcome and economic benefit of using Galectin-3 , for example, like the HUMANA study on the role of Galectin-3 measurements
at admission in the active discharge of HF patients. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit 7.1 
 Target Development Plan and Timeline 
  

	(a)	The Parties will negotiate in good faith to agree upon [***] for the [***] within [***] ([***]) days of the effective date; 

 

	(b)	BMX will [***] within [***] ([***]) days after agreement is reached pursuant to the preceding paragraph (a); 

 

	(c)	BMX will [***] by [***]; 

  

	(d)	BMX will [***] or [***] for the [***] by [***]; and 

  

	(e)	BMX will [***] by [***], or, if later, as soon as reasonably practicable [***]. 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit 12.12 
 Alternative Dispute Resolution 
 1.1 The parties shall attempt in good faith to
resolve promptly any dispute arising out of or relating to this Agreement by negotiation. If the dispute cannot be resolved in the normal course of business, any interested party shall give the other party written notice of any such dispute not
resolved, after which the dispute shall be referred to senior executives of both parties, who shall likewise attempt to resolve the dispute. 

1.2 If the dispute has not been resolved by negotiation within forty-five (45) days of the disputing party’s written notice, or if the parties
fail to meet within twenty (20) days as from such notice, the parties shall endeavour to settle the dispute by mediation under the then current CPR Mediation Procedure. 
 Unless otherwise agreed, both parties or each individual party may request the International Institute for Conflict Prevention and Resolution (CPR) to appoint an independent mediator selected from the CPR
Panels of Distinguished Neutrals. The language of mediation shall be English and the seat of mediation shall be Boston, MA. 
 1.3 All
communications during the negotiation and mediation pursuant to Section 1.1 or 1.2 above are confidential and shall be treated as compromise and settlement negotiations for purposes of applicable rules of evidence and any additional
confidentiality and professional secrecy protections provided by applicable law. 
 1.4 If the dispute has not been resolved by non-binding
means as provided in Section 1.2 above within sixty (60) days of the appointment of the mediator or if one of the parties has informed the other party in writing that it is not willing to start or proceed with the mediation as contemplated
in Section 1.2 hereof, the dispute shall be finally and exclusively resolved by arbitration in Boston, MA, by a sole independent arbitrator appointed and acting in accordance with the then current Rules For Non Administered Arbitration of
International Disputes of the International Institute for Conflict Prevention and Resolution (formerly known as CPR Institute for Dispute Resolution). The language of the arbitration shall be English. The award shall be final, binding and
enforceable by any court having jurisdiction for that purpose. The Neutral Organisation designated to perform the functions specified in Rules 5, 6 and 7 shall be the CPR. 
 1.5 The arbitrator may not award punitive damages. The parties hereby waive the right to punitive damages. 
 1.6 This Article shall, however, not be construed to limit or to preclude either party from bringing any action in any court of competent jurisdiction for injunctive or other provisional relief as
necessary or appropriate. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.Letter Agreement, Wayne K. Shephard

 Exhibit 10.20 
 BG MEDICINE 
 610N Lincoln St., Waltham, Massachusetts 02451 

T 781.890.1199 F 781.895.1119 W bg-medicine.com 
 May 12, 2009 
 Wayne Kendall Shepherd 

16361 Fox Valley Drive 
 San Diego, CA 92127

 Dear Wayne: 
 On
behalf of BG Medicine, Inc. (the “Company”), and the entire Board of Directors of the Company, I am delighted to offer you employment with the Company. Your initial position will be Vice President, Market Development, reporting to
me (or my designee). We anticipate that your employment will start effective June 1, 2009 (the “Start Date”). In order to effectuate an orderly and productive transition to your new role, you will be required to move to the
Northeast/mid Atlantic region prior to the Start Date (the expenses associated with such relocation are described in Section 1(e) below). In addition, during the first sixty (60) days following the Start Date, you will be required to work
at least three (3) days per week at Company’s offices in Waltham, Massachusetts. 
 In your position, you will have
responsibility for guiding the Company’s sales efforts and coordinating all field based market development activities in North America. In addition, you will be responsible for coordinating sales efforts, training and local marketing activities
with commercial clinical laboratories, medical centers and immunodiagnostics distribution partners. As you progress with the Company, your position and assignments are, of course, subject to change. As a Company employee, we expect that you will
perform any and all duties and responsibilities normally associated with your position in a satisfactory manner and to the best of your abilities at all times. 
 This offer letter and the accompanying documents and agreements summarize and set forth important terms about your employment with the Company. As is generally true for Company employees, you will be
employed on an at-will basis, which means that neither you nor the Company is guaranteeing this employment relationship for any specific period of time. Either of us may choose to end the employment relationship at any time, for any reason, with or
without notice (subject to the potential severance payments and benefits described in Section 2). In addition, you should understand that the descriptions of benefits and other compensation arrangements set forth herein are meant to be summary
in form and may be subject to change. If any benefit is subject to a benefit plan, the terms of that plan will control. The Company reserves the right to alter, supplement or rescind its employment procedures, benefits or policies (other than the
employment at-will policy) at any time in its sole and absolute discretion and without notice. 

 1. Compensation. 

a. Salary. Your initial base pay will be at a rate of $6,666.66 on a semi-monthly basis ($160,000.00 on an
annualized basis), minus customary deductions for federal and state taxes and the like, and in accordance with the Company’s normal payroll practices. 
 b. Performance Bonus. You will also be eligible to receive an incentive bonus of up to $60,000, based on your achievement of specific milestones and revenue targets as determined by the
EVP & General Manager Diagnostics and the Company’s Compensation Committee. The 2009 incentive plan will be pro-rated based on your employment start date and accomplishment of specific milestones (comprising 80% of the bonus) and
revenue target (comprising 20% of the bonus), and will be payable following quarter end assessment on September 30, 2009 and December 31, 2009. For 2010 and beyond, the incentive plan will primarily be based on revenue target achievement
(comprising 80% of the bonus) with the remaining portion related to milestone achievement (comprising 20% of the bonus). The revenue target of your performance bonus in 2010 will not be capped and will enable additional payment beyond target for
revenue that exceeds the annual revenue goals. For 2010 and beyond, your incentive bonus related to the revenue target portion of your incentive plan will be paid on a quarterly basis and the milestone portion of your incentive plan will be paid
following the completion of each plan year. 
 c. Stock Options. Subject to the terms of and contingent
upon your execution of a stock option agreement (the “Option Agreement”) issued pursuant to the Company’s 2001 Stock Option and Incentive Plan, as amended (the “Option Plan”), and subject to Board approval, you will be
granted an option to purchase 75,000 shares of common stock of the Company at an exercise price equal to the fair market value of the stock at the time of the grant as determined by the Board of Directors. This option will vest 25% on the first
anniversary of your first day of employment and thereafter the remaining 75% shall vest on a quarterly basis on the last day of each quarter over a period of three years, provided that you remain employed on the vesting day. If the Company is
acquired in a transaction involving a “Change of Control” (as defined in the Option Agreement), then the Company will immediately accelerate the vesting of unvested option shares under the Option Plan and Option Agreement equal to an
amount of such shares that would have vested during the nine (9) month period following the Change of Control, pursuant to the terms and conditions of the Option Plan and Option Agreement, with any remaining unvested option shares (after giving
effect to the aforementioned vesting acceleration) to vest in equal monthly installments during the remainder of the vesting period described above. All shares granted hereunder shall be treated as Incentive Stock Options, to the extent allowable
under Section 422 of the Internal Revenue Code of 1986, as amended and any successor statute, regulation and guidance thereto. 

 d. Benefits. You will be eligible to participate in the
Company’s benefit plans to the same extent as, and subject to the same terms, conditions and limitations applicable to, other Company employees of similar rank and tenure. Summaries of each of the Company’s benefit plans are available to
you. In addition, you will be reimbursed for all reasonable out-of-pocket expenses incurred during the performance of your duties, in accordance with the Company’s reimbursement policies as established or modified from time to time by the
Company. Each calendar year you will be eligible to accrue up to four (4) weeks vacation and up to twelve (12) holidays (initial employment year will be pro-rated), as set forth by the Company and subject to the Company’s vacation and
holiday policies as in effect from time to time. 
 e. Relocation Expenses. The Company shall reimburse
you up to a maximum amount of $20,000 for the following expenses associated with moving to the Northeast/mid Atlantic region: (i) one (1) round trip coach airline ticket for you and each of your immediate family members to fly from your
current home location to the Northeast/mid Atlantic region, for the purpose of researching and identifying a suitable house in the Northeast/mid Atlantic region (i.e., a “house hunting” trip); (ii) one (1) one-way coach
airline ticket for you and each of your family members to fly from your current home location to the Northeast or mid Atlantic region or mileage should you choose to drive, for the purpose of moving to the Northeast/mid Atlantic region; and
(iii) the reasonable cost of transporting your household and personal belongings to your new home in the Northeast/mid Atlantic region. The expenses described above will be paid by you and reimbursed upon submission and approval of appropriate
receipts and documentation. In addition to the reimbursement outlined above, the Company will provide you with a relocation bonus of $13,333.32 (i.e., one (1) month of your base salary) following the completion of your relocation to the
Northeast/mid Atlantic region. This amount will be payable in the form of a bonus and will be subject customary deductions for federal and state taxes and the like. 
 2. Severance Pay and Benefits upon Termination of Employment. 
 a. Termination Other Than for Cause, Death or Disability. Should the Company terminate your employment for reasons other than for “Cause”, “Death” or “Disability” (as
these terms are defined in the Option Agreement), and conditioned upon: (i) your execution of a separation agreement which contains, among other things, a full and general release of claims to the Company and its affiliates and their respective
directors, officers, agents and employees, in a form satisfactory to the Company, and (ii) your compliance with your obligations set forth in your Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment of Inventions
Agreement (herein, the “Non-Competition and Confidentiality Agreement”), then the Company will provide you with: (A) payments equal to three (3) months of your then current base salary, payable in installments over three
(3) months, and in accordance with the Company’s normal payroll 

 
practices; and (B) if the Company is subject to the Consolidated Omnibus Budget Reconciliation Act (“COBRA”) or similar state law and if you properly elect to receive benefits
under COBRA, three (3) months of your COBRA premiums at the Company’s normal rate of contribution for employees. In the event that you are eligible for the severance pay and benefits described in this Section 2(a), you shall not be
eligible for and shall not receive the severance pay and benefits described in Section 2(b). 
 b.
Termination upon a Change of Control. Should the Company terminate your employment within six (6) months following a “Change of Control” (as defined in the Option Agreement) of the Company and for reasons other than for
“Cause”, “Death” or “Disability” (as these terms are defined in the Option Agreement), and conditioned upon: (i) your execution of a separation agreement which contains, among other things, a full and general
release of claims to the Company and its affiliates and their respective directors, officers, agents and employees, in a form satisfactory to the Company, and (ii) your compliance with your obligations set forth in your Non-Competition and
Confidentiality Agreement, then the Company will provide you with: (A) payments equal to three (3) months of your then current base salary, payable in installments over three (3) months, and in accordance with the Company’s
normal payroll practices; and (B) if the Company is subject to COBRA or similar state law and if you properly elect to receive benefits under COBRA, three (3) months of your COBRA premiums at the Company’s normal rate of contribution
for employees. In the event that you are eligible for the severance pay and benefits described in this Section 2(b), you shall not be eligible for and shall not receive the severance pay and benefits described in Section 2(a). 

c. Any severance pay or benefits provided under Sections 2(a) or 2(b) (as applicable) will commence within ten
(10) days following your execution and non-revocation of the separation agreement described in such sections. Such severance pay and benefits shall be paid in addition to any portion of your salary that is accrued but not yet paid as of the
termination date, any expenses that are properly incurred by not yet reimbursed as of the termination date, and benefits provided through the termination date (in accordance with the terms of applicable benefits plans), which shall be provided to
you regardless of reason for termination. 
 d. Nothing in Section 2 shall alter your status as an
at-will employee. 
 3. Certifications by You. By signing this offer letter, you are certifying to the Company that:
(i) your employment with the Company does not, and will not, require you to breach any agreement entered into by you prior to employment with the Company (i.e., you have not entered into any agreements with previous employers that are in
conflict with your obligations to the Company) or to violate any order, judgment or injunction applicable to you; (ii) to the extent you are subject to restrictive covenants with any prior employer, or any order, judgment or injunction, that
may affect your employment with the Company, you have provided the Company with a copy of that agreement, order or judgment; and (iii) all facts you have presented or will present to the Company are accurate and true, including, but not limited
to, all oral and written statements made to the Company pertaining to education, training, 

 
qualifications, licensing and prior work experience on any job application, resume or c.v., or in any interview. Please understand that the Company does not want you to disclose any
confidential information belonging to a previous employer or to incorporate the proprietary information of any previous employer into the Company’s proprietary information and expects that you will abide by restrictive covenants to prior
employers. 
 4. Required I-9 Documentation. For purposes of completing the INS I-9 form, you must provide us sufficient
documentation to demonstrate your eligibility to work in the United States on or before your first day of employment. If you have any questions about what documentation you must provide, please contact Stacie Rader, our Vice President, Human
Resources. Your employment with the Company is conditioned on your eligibility to work in the United States. 
 5.
Confidentiality and Other Obligations by You. As part of your employment with the Company, you have been, and will be, exposed to, and provided with, valuable confidential and/or trade secret information concerning the Company and its present
and prospective clients. As a result, in order to protect the Company’s legitimate business interests, you agree, as a condition of your employment, to enter into the enclosed Non-Competition and Confidentiality Agreement. You must sign and
return the Non-Competition and Confidentiality Agreement before beginning your employment with the Company. 
 6. Compliance
with Section 409A and Section 280G of the Code. 
 a. Notwithstanding any other provision of
this Agreement to the contrary, if any amount (including imputed income) to be paid to you pursuant to this Agreement as a result of your termination of employment is “deferred compensation” subject to Section 409A of the Internal
Revenue Code of 1986, as amended and any successor statute, regulation and guidance thereto (“Section 409A of the Code”), and if you are a “Specified Employee” (as defined under Section 409A of the Code) as of the date of
your termination of employment hereunder, then, to the extent necessary to avoid the imposition of excise taxes or other penalties under Section 409A of the Code, the payment of benefits, if any, scheduled to be paid by Company to you hereunder
during the first 6-month period following the date of a termination of employment hereunder shall not be paid until the date which is the first business day after six (6) months have elapsed since your termination of employment for any reason
other than death. Any deferred compensation payments delayed in accordance with the terms of this Section 6a shall be paid in a lump sum after 6-months have elapsed since your termination of employment. Any other payments will be made according
to the schedule provided for herein. 
 b. If any of the benefits set forth in this Agreement are deferred
compensation under Section 409A of the Code, any termination of employment triggering payment of such benefits must constitute a “separation from service” under Section 409A of the Code before distribution of such benefits can
commence. For purposes of clarification, this Section 6b shall not cause any forfeiture of benefits on your part, but shall only act as a delay until such time as a “separation from service” occurs. 

 c. It is intended that each installment of the payments and benefits
provided under this Agreement shall be treated as a separate “payment” for purposes of Section 409A of the Code. Neither the Company nor you shall have the right to accelerate or defer the delivery of any such payments or benefits
except to the extent specifically permitted or required by Section 409A of the Code. 
 d. Any
reimbursements or direct payment of your expenses subject to Section 409A of the Code must be substantiated by appropriate receipts and documentation, and you must submit any request for reimbursement of expenses no later than ninety
(90) days following the date that such expense is incurred, in accordance with the Company’s reimbursement policy regarding same. The Company may request additional documentation or a further explanation to substantiate any expense
submitted for reimbursement, and retains the discretion to approve or deny a request for reimbursement. Any reimbursements or direct payment of your expenses subject to Section 409A of the Code shall be made no later than the end of the
calendar year following the calendar year in which such expense is incurred by you. Any reimbursement or right to direct payment of your expense in one calendar year shall not affect the amount that may be reimbursed or paid for in any other
calendar year and a reimbursement or payment of your expense (or right thereto) may not be exchanged or liquidated for another benefit or payment. 
 e. Notwithstanding any other provision of this Agreement to the contrary, the Agreement shall be interpreted and at all times administered in a manner that avoids the inclusion of compensation in
income under Section 409A(a)(1) of the Code. Any provision inconsistent with Section 409A of the Code will be read out of the Agreement. For purposes of clarification, this Section 6e shall be a rule of construction and interpretation
and nothing in this Section 6e shall cause a forfeiture of benefits on the part of you. 
 7. General. This offer
letter, together with the Non-Competition and Confidentiality Agreement and the Option Agreement and any other agreements specifically referred to herein, embodies the entire agreement and understanding between the parties hereto with respect to the
subject matter hereof, and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. This offer letter’s terms may be modified or amended only by written agreement executed by the parties hereto,
and its terms may be waived, or consent for the departure therefrom granted, only by a written document executed by the party entitled to the benefits of such terms or provisions. Each such waiver or consent will be effective only in the specific
instance and for the purpose for which it was given, and will not constitute a continuing waiver or consent. Because our employment discussions and the terms of your employment are confidential, it is understood that you shall not disclose the fact
or terms of such discussions or the terms of your employment with the Company to anyone other than your immediate family and your legal or financial advisor at any time, absent prior written consent from the Company. 

 The Company may assign its rights and obligations hereunder to any person or entity that
succeeds to all or substantially all of the Company’s business. You may not assign your rights and obligations hereunder without the prior written consent of the Company and any such attempted assignment by you without the prior written consent
of the Company will be void. This offer letter and the rights and obligations of the parties hereunder will be construed in accordance with and governed by the law of the Commonwealth of Massachusetts, without giving effect to the conflict of law
principles thereof. By accepting this offer of employment, you agree that any action, demand, claim or counterclaim in connection with any aspect of your employment with the Company, or any separation of employment (whether voluntary or involuntary)
from the Company, shall be resolved in a court of competent jurisdiction in Massachusetts, by a judge alone, and you waive and forever renounce your right to a trial before a civil jury. 

This offer shall remain open, unless sooner revoked by the Company, through May 15, 2009. 

Please acknowledge acceptance of this employment offer by signing, dating, and indicating your start date below. Keep one copy for your
files and return one executed copy to Stacie Rader, Vice President, Human Resources. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK] 

 Wayne, we look forward to having you on the team. 

 

			
	Very truly yours,
	
	BG Medicine, Inc.
		
	By:	 	/s/ C. Douglas White
	C. Douglas White
	EVP and General Manager Diagnostics

  

	
	Accepted and Agreed to:
	
	/s/ Wayne Kendall Shepherd
	Wayne Kendall Shepherd
	
	June 1, 2009
	Start Date

 BG MEDICINE 
 610N Lincoln St., Waltham, Massachusetts 02451 
 T 781.890.1199 F 781.895.1119 W
bg-medicine.com 
 May 24, 2010 

Wayne Kendall Shepherd 
 16361 Fox Valley Drive

 San Diego, CA 92127 

Re:    Amendment to May 12, 2009 Employment Agreement 

Dear Wayne, 
 The purpose of
this document (the “Employment Agreement Amendment”) is to amend specific paragraphs of the May 12, 2009 employment agreement (the “Employment Agreement”) between you and BG Medicine, Inc. (the “Company”) in order
to reflect negotiated and mutually acceptable new provisions pertaining to your continued employment with the Company. 
 In
consideration of the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree that the Employment Agreement will be amended as follows, effective
as of the date on which you sign this Employment Agreement Amendment (the “Effective Date”): 
 1. The second sentence
of the introductory paragraph of the Employment Agreement is hereby replaced in its entirety by the following: 
 “Your
position will be VP, Sales and Marketing, reporting to me (or my designee).” 
 2. Section 1.a. of the
Employment Agreement is hereby replaced in its entirety by the following: 
 “a. Salary. Your base pay will be at a
rate of $7,708 on a semi-monthly basis ($185,000 on an annualized basis), minus customary deductions for federal and state taxes and the like, and in accordance with the Company’s normal payroll practices.” 

3. Section 1.b. of the Employment Agreement is hereby replaced in its entirety by the following: 

“b. Milestone Bonus. For 2010 and beyond, the Company shall provide you with an annual milestone bonus of up to twenty percent
(20%) of your then-current base salary (the “Milestone Bonus”), less standard employment withholdings and deductions, based on achievement during the applicable bonus year of certain corporate and individual milestones determined in
advance by the Company. Your achievement of such milestones shall be determined by the Company in its sole discretion and, if such milestones are met, the Milestone Bonus shall be paid on the next following regular payday following the meeting of
the final applicable milestone as determined by the Compensation Committee of the Board of Directors. The Milestone Bonus is 

 
conditioned upon your continuous employment with the Company through the meeting of the above-described milestones. The offer of a Milestone Bonus, of course, is not a guarantee of employment.
Your employment with the Company remains at-will, and either party may terminate such employment at any time and for any reason, subject to Section 2 herein. If you are no longer an employee of the Company, then you will not be entitled to the
Milestone Bonus even if the above-described milestones subsequently are met.” 
 4. Section 1.c. of the Employment
Agreement is hereby amended by adding the following paragraph, following the first paragraph of such Section 1.c.: 
 “Subject to Board approval, and further subject to the terms of and contingent upon your execution of a stock option agreement (the “Additional Option Agreement”) issued pursuant to the
Company’s 2001 Stock Option and Incentive Plan, as amended (the “Option Plan”), you will be granted an option to purchase 50,000 shares of common stock of the Company at an exercise price equal to the fair market value of the stock at
the date of the grant (the “Grant Date”) as determined by the Board of Directors. This option will vest as to 33% of the total amount of granted shares on the first (1st) anniversary of the Effective Date of the Employment Agreement Amendment hereto, and thereafter shall vest as to
the remaining 67% of granted shares on a quarterly basis on the last day of each quarter over a period of two (2) years following the 1st anniversary, with any fractional share to be rounded down in each vesting quarter and made whole in the final vesting
quarter (i.e., 4,187 shares scheduled to vest in the first 7 quarters and 4,191 shares scheduled to vest in the
8th quarter), provided that you remain employed on each
such vesting day. If the Company is acquired in a transaction involving a “Change of Control” (as defined in the Option Agreement), then the Company will immediately accelerate the vesting of unvested option shares under the Additional
Option Agreement equal to an amount of such shares that would have vested during the nine (9) month period following the Change of Control, pursuant to the terms and conditions of the Additional Option Agreement, with any remaining unvested
option shares (after giving effect to the aforementioned vesting acceleration) to vest in equal monthly installments during the remainder of the vesting period described above. All shares granted hereunder shall be treated as Incentive Stock
Options, to the extent allowable under Section 422 of the Internal Revenue Code of 1986, as amended and any successor statute, regulation and guidance thereto. 
 5. Section 1 of the Employment Agreement is hereby amended by adding the following paragraphs, following Section 1.e.: 
 f. Travel Expenses. The Company shall reimburse you for all ordinary and reasonable out-of-pocket expenses incurred by you while traveling away from the Company’s Waltham, Massachusetts office
in furtherance of Company’s business. Such reimbursement shall be in accordance with Company’s policies with respect thereto as in effect from time to time, and in accordance Section 6 herein.” 

g. New Commission Plan. If you remain continuously employed by the Company through the successful premarket approval of Galectin-3 by
the Federal Food and Drug Administration under section 501(k), then the Company will provide you with a new sales commission plan (the “Commission Plan”). The terms 

 
and conditions of the Commission Plan shall be determined by the Company and it Compensation Committee in its sole discretion, and shall be provided to you within forty-five (45) days
following the above-described premarket approval. Eligibility for the Commission Plan is conditioned upon your continuous employment with the Company through the above-described premarket approval. The offer of the Commission Plan, of course, is not
a guarantee of employment. Your employment with the Company remains at-will, and either party may terminate such employment at any time and for any reason, subject to Section 2 herein. If you are no longer an employee of the Company, then you
will not be entitled to the Commission Plan even if the above-described premarket approval subsequently occurs.” 

Except as specifically modified herein, the terms of the Employment Agreement (and any agreements and/or agreement provisions
specifically referenced as surviving therein), shall remain in full force and effect. Without limiting the foregoing, the parties expressly acknowledge and agree that this Employment Agreement Amendment shall not impact your continuing obligations
under your Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment of Inventions Agreement, which remain in full force and effect according to their terms. 
 The parties acknowledge and agree that this amendment constitutes a modification of the Employment Agreement by written agreement executed by the parties, as permitted by Section 7 of the Employment
Agreement. 
 You expressly acknowledge and agree that neither this Employment Agreement Amendment nor the parties’
performance hereunder constitutes “good reason” under any agreement between you and the Company or any Company policy or plan applicable to you, and you irrevocably waive, renounce and relinquish your right to claim that it constitutes
“good reason” under any such agreement, policy or plan. 
 By signing this Employment Agreement Amendment, you
acknowledge that you have been afforded sufficient time to understand its terms, that your agreement herein is made voluntarily and knowingly, and that neither the Company nor its representatives have made any representations inconsistent with its
provisions. This Employment Agreement Amendment may be signed on one or more copies, each of which when signed will be deemed to be an original, and all of which together will constitute one and the same agreement. 

 Wayne, we consider you a key member of our team, and look forward to continuing a productive
and mutually beneficial relationship. If the foregoing correctly sets forth our understanding, please sign, date and return the enclosed copy of this Employment Agreement Amendment to Stacie Rader within five (5) days. 

 

			
	Very truly yours,
	
	BG, Medicine, Inc.
		
	By:	 	/s/ Pieter Muntendam
		
	Dated:	 	June 7, 2010

  

	
	Acknowledged and Agreed:
	
	/s/ Wayne Kendall Shepherd
	Wayne Kendall Shepherd
	
	Dated: 6/3/10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]